Recent advances in the discovery of small molecule mTOR inhibitors

Future Medicinal Chemistry

Volumn 2, Issue 10, 2010, Pages 1577-1589

  Roychowdhury, Abhijit ^a   Sharma, Rajiv ^a   Kumar, Sanjay ^a  

^a Piramal Enterprises Limited   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1H PYRAZOLO[3,4 D]PYRIMIDINE; 4 (PYRIDO[2,3 D]PYRIMIDINE 4 YL)MORPHOLINE; AP 23841; AP 24170; BC 210; BIS MORPHOLINO TRIAZINE; DEFOROLIMUS; ENDEAVOR; EVEROLIMUS; FK 506 BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; TRIMAXX; UNCLASSIFIED DRUG; ZOMAXX; ZOTAROLIMUS;

BINDING SITE; CELL CYCLE PROGRESSION; CORONARY ARTERY DISEASE; CRYSTAL STRUCTURE; DRUG ELUTING STENT; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; EUROPE; FOOD AND DRUG ADMINISTRATION; HEART TRANSPLANTATION; HELA CELL; HUMAN; IC 50; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; MELANOMA; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; T LYMPHOCYTE; UNITED STATES;

ANIMALS; ANTIFUNGAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; SMALL MOLECULE LIBRARIES; TOR SERINE-THREONINE KINASES;

EID: 77958071860     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.233     Document Type: Review

References (61)

1. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8, 179-183 (2005
2. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671-688 (2006
3. Baldo P, Cecco S, Giacomin E et al. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets 8, 647-665 (2008
4. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171(2004
5. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007
6. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol. Med. 11, 353-361 (2005
7. Martin DE, Hall MN. The expanding TOR signaling network. Curr. Opin. Cell Biol. 17, 158-166 (2005
8. Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 30, 35-42 (2005
9. Dos Santos S, Delattre AI, De Longueville F et al. Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kB and PI3K/mTOR signaling pathways. Ann. N.Y. Acad. Sci. 1096, 70-77 (2007
10. Weinstein SL, Finn AJ, Dave SH et al. Phosphatidylinositol 3-kinase and mTOR mediate lipopolysaccharide-stimulated nitric oxide production in macrophages via interferon-b. J. Leukoc. Biol. 67, 405-414 (2000
11. Kristof AS, Marks-Konczalik J, Billings E et al. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-g is regulated by mammalian target of rapamycin. J. Biol. Chem. 278, 33637-33644 (2003
12. Farkas S, Hornung M, Sattler C et al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int. J. Colorectal Dis. 21, 747-753 (2006
13. Matsuda C, Ito T, Song J et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin. Exp. Immunol. 148, 348-359 (2007
14. Deore V, Yewalkar N, Bhatia D et al. Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg. Med. Chem. Lett. 19, 2949-2952 (2009
15. Cota D, Proulx K, Smith KA et al. Hypothalamic mTOR signaling regulates food intake. Science 312, 927-930 (2006
16. Harrison DE, Strong R, Sharp ZD et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395 (2009
17. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550-562 (2009
18. Liu P, Cheng H, Roberts TM et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644 (2009
19. Brachmann S, Fritsch C, Maira SM et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr. Opin. Cell Biol. 21, 194-198 (2009
20. Guertin DA, Sabatini, DM. The pharmacology of mTOR inhibition: the quest for effective cancer therapies reveals insight into the regulation and function of the mammalian target of rapamycin. Science Signaling 2 (67), 24 (2009
21. Laplante M, Sabatini DM. mTOR signaling at a glance. J. Cell Sci. 122, 3589-3594 (2009
22. Liu Q, Thoreen C, Wang J et al. mTOR mediated anticancer drug discovery. Drug Discov. Today Therapeutic Strat. 6(2), 47-55 (2010
23. Huang J, Wu S, Wu CL et al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 69, 6107-6114 (2009
24. Raje N, Kumar S, Hideshima T et al. Anderson Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104, 4188-4193 (2004
25. Vignot S, Faivre S, Aguirre D et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Annal. Oncology 16, 525-537 (2005
26. Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin. Pharmacol. Ther. 82, 381-388 (2007
27. Sarbassov DD, Ali SM et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006
28. Choi J, Chen J, Schreiber SL et al. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273, 239-342 (1996
29. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006
30. Kurmasheva RT, Huang S, Houghton PJ. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer 95, 955-960 (2006
31. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. 2, 222-232 (2003
32. Chen Y, Zheng Y et al. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 22, 3937-3942 (2003
33. Neuhaus P, Klupp J, Langrehr JM. mTOR inhibitors: an overview. Liv. Transplantation 7, 473-484 (2001
34. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J. Antibiot. (Tokyo) 28, 727-732 (1975
35. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55, 48-51 (1977
36. Cardenas ME, Cruz MC, Del Poeta M et al. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev. 12, 583-611 (1999
37. Singh N, Heitman J. Antifungal attributes of immunosuppressive agents: new paradigms in management and elucidating the pathophysiologic basis of opportunistic mycoses in organ transplant recipients. Transplantation 77, 795-800 (2004
38. Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 58, 373-395 (1996
39. Tamburini J, Chapuis N, Bardet V et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111, 379-382 (2008
40. Tamburini J, Green AS, Bardet V et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114, 1618-1627 (2009
41. Menear KA, Gomez S, Malagu K et al. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Bioorg. Med. Chem. Lett. 19, 5898-5901 (2009
42. Richard DJ, Verheijen JC, Yu K et al. Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Ka. Bioorg. Med. Chem. Lett. 2010, 20, 2654-2657 (2010
43. Malagu K, Duggan H, Menear K et al. The discovery and optimization of pyrido[2,3-d] pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase. Bioorg. Med. Chem. Lett. 19, 5950-5953 (2009
44. Garcia-Martinez JM, Moran J, Clarke RG et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29-42 (2009
45. Zask A, Verheijen JC, Curran K et al. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. J. Med. Chem. 52, 5013-5016 (2009
46. Zask A, Kaplan J, Verheijen JC et al. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors. J. Med. Chem. 52, 7942-7945 (2009
47. Richard DJ, Verheijen JC, Curran K et al. Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: discovery of highly potent and selective analogs with improved human microsomal stability. Bioorg. Med. Chem. Lett. 19, 6830-6835 (2009
48. Curran KJ, Verheijen JC, Kaplan J et al. Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 1-substituent. Bioorg. Med. Chem. Lett. 20, 1440-1444 (2010
49. Verheijen JC, Richard DJ, Curran K et al. 2-arylureidophenyl-4-(3-oxa-8- azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability. Bioorg. Med. Chem. Lett. 20, 2648-2653 (2010
50. Zask A, Verheijen JC, Richard DJ et al. Discovery of 2- ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 2644-2647 (2010
51. Verheijen JC, Yu K, Toral-Barza L et al. Discovery of 2-arylthieno[3,2-d] pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Bioorg. Med. Chem. Lett. 20, 375-379 (2010
52. Dehnhardt CM, Venkatesan AM, Santos ED et al. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. J. Med. Chem. 53 (2), 798-810 (2010
53. Venkatesan AM, Dehnhardt CM, Chen Z et al. Novel imidazolopyrimidines as dual PI3-kinase/mTOR inhibitors. Bioorg. Med. Chem. Lett. 20, 653-656 (2010
54. Tsou HR, MacEwan G, Birnberg G et al. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl) methylene-4-hydroxybenzofuran-3(2H) -ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 2321-2325 (2010
55. Kaplan J, Verheijen JC, Brooijmans N et al. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d] pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Bioorg. Med. Chem. Lett. 20, 640-643 (2010
56. Knight SD, Adams ND, Burgess JL et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapapmycin. ACS Med. Chem. Lett. 1(1), 39-43 (2010
57. Raynaud FI, Eccles SA, Patel S et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8(7), 1725-1738 (2009
58. Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther. 8(1), 1-9 (2009
59. Marone R, Cmiljanovic V, Giese B et al. Targeting phosphoinositide 3-kinase-moving towards therapy. Biochim. Biophys. Acta. 1784, 159-185 (2008
60. Maira SM, Stauffer F, Schnell C et al. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc. Trans. 37, 265-272 (2009
61. Maira SM, Furet P, Stauffer F. Discovery of novel anticancer therapeutics targeting the PI3K/AKt/mTOR pathway. Future Med. Chem. 1(1), 137-155 (2009